Highest-materiality recent filing
Biogen Q2 revenue $2.7B (+3% YoY); GAAP EPS $0.66, Non-GAAP $3.60; Growth Portfolio up 24% to $1.06B
Total revenue $2.7B (+3% YoY); GAAP diluted EPS $0.66 (down 85%), Non-GAAP diluted EPS $3.60 (down 34%).
Q2 2026: ~$164M pre-tax IPR&D charge; EPS impact ~$0.95 per share.
Biogen shareholders elect all 10 director nominees and ratify auditor at 2026 annual meeting
All ten board nominees elected; highest vote against for Eric K. Rowinsky (28.2M against of 121.9M voted).
Biogen amends 8-K to note Apellis acquisition not significant, no financial statements required
Acquisition of Apellis closed May 14, 2026; deemed not significant under Regulation S-X after further analysis.
Biogen completes $5.3B Apellis acquisition; adds SYFOVRE/EMPAVELI, $41/share + CVRs
Biogen acquired Apellis for $41/share cash plus CVRs worth up to $4/share tied to SYFOVRE net sales milestones.
Biogen Q1 revenue $2.5B, EPS beat; proposes Apellis acquisition, updates FY2026 guidance
Q1 rev $2.5B (+2% YoY); GAAP EPS $2.15 (+31%); Non-GAAP EPS $3.57 (+18%).
Biogen warns of $34M pre-tax IPR&D and upfront charge in Q1 2026, impacting EPS by $0.19
Preliminary estimate: ~$34M pre-tax acquired in-process R&D, upfront and milestone expense for Q1 2026.
Biogen to acquire Apellis for $41/share plus up to $4 CVR per share
Upfront cash consideration of $41.00 per Apellis share; one CVR per share entitling holders to up to $4.00 additional.
Biogen Chief Legal Officer Susan H. Alexander to depart end of May 2026
Susan H. Alexander, Chief Legal Officer, will leave Biogen effective end of May 2026.
Biogen Chair Caroline Dorsa to step down; Dr. Maria C. Freire elected as new Chair
Chair Caroline Dorsa will not stand for re-election at the 2026 Annual Meeting; decision unrelated to any disagreement.
Biogen Q4 revenue $2.3B, GAAP EPS loss $(0.33); FY2025 Non-GAAP EPS $15.28 beats guidance
Q4 total revenue $2.3B (-7% YoY); GAAP diluted EPS $(0.33); Non-GAAP diluted EPS $1.99.
Biogen expects ~$222M pre-tax charge in Q4 2025 for IPR&D and milestone costs; EPS impact ~$1.26
Q4 2025 acquired IPR&D, upfront and milestone expense estimated at ~$222M pre-tax.
Biogen Q3 revenue $2.5B (+3% YoY); non-GAAP EPS $4.81 (+18%); FY25 guidance raised
GAAP diluted EPS $3.17 (+19% YoY); Non-GAAP diluted EPS $4.81 (+18% YoY).
Biogen expects ~$2M pre-tax IPR&D charge for Q3, impact of ($0.01)/share
Preliminary estimate: acquired IPR&D, upfront & milestone expense of ~$2M pre-tax.
Biogen Q2 revenue $2.6B (+7% YoY), GAAP EPS $4.33, raises FY2025 guidance
Q2 2025 revenue $2.6B (+7% YoY); GAAP EPS $4.33 (+8%); Non-GAAP EPS $5.47 (+4%).
Biogen expects Q2 2025 charge of $46M for IPR&D, reducing EPS by ~$0.26
Pre-tax acquired IPR&D, upfront and milestone expense of ~$46M in Q2 2025.
All 11 nominees elected to one-year terms; Caroline Dorsa received the most votes against (25.5M).
Biogen issues $1.75B in three tranches of senior notes to refinance maturing 2025 debt
$400M 5.050% notes due 2031, $650M 5.750% notes due 2035, $700M 6.450% notes due 2055.
Biogen Q1 revenue up 6% to $2.43B; Non-GAAP EPS $3.02 impacted by $165M Stoke upfront
GAAP diluted EPS $1.64, Non-GAAP $3.02; both down YoY due to ~($0.95) impact from Stoke upfront payment.
Biogen Q4 revenue up 3% to $2.5B, non-GAAP EPS $3.44; FY2025 guidance calls for revenue decline
Q4 total revenue $2.5B (+3% YoY); GAAP EPS $1.83, non-GAAP EPS $3.44 (+17% YoY).
Biogen appoints Sean Godbout as Chief Accounting Officer effective March 1, 2025
Sean Godbout to succeed Robin Kramer as CAO and principal accounting officer; Kramer transitions to CFO role upon McDonnell's retirement.
Biogen Q3 GAAP EPS $2.66, revenue $2.466B; raises FY2024 Non-GAAP EPS guidance to $16.10-$16.60
Q3 2024 revenue $2.466B (-3% YoY); GAAP diluted EPS $2.66 vs ($0.47) in Q3 2023.
Biogen CFO Michael McDonnell to retire Feb 2025; Robin Kramer named successor
Michael McDonnell to retire as CFO effective February 28, 2025, after serving since August 2020.
Biogen elects Dr. Lloyd Minor and Prof Sir Menelas Pangalos to Board
Board size increased; Dr. Lloyd Minor effective Oct 1, 2024; Prof Sir Mene Pangalos effective Jan 1, 2025.
Biogen enters $1.5B unsecured revolving credit facility, terminates prior facility
$1.5B five-year unsecured revolving credit facility; no borrowings drawn at closing.
Biogen Q2 revenue flat at $2.47B; Non-GAAP EPS up 31% to $5.28; raises FY2024 guidance
Q2 total revenue $2,465M flat YoY; GAAP diluted EPS $4.00 (-2%), Non-GAAP diluted EPS $5.28 (+31%).
Biogen shareholders approve officer exculpation amendment and elect nine directors at annual meeting
Certificate of Amendment filed to allow officer exculpation to extent permitted by Delaware law; approved with 103.1M votes for, 16.3M against.
Biogen Q1 EPS up 8% non-GAAP; LEQEMBI sales triple Q4 to $19M; reaffirms FY guide
Q1 total revenue $2.3B (-7% YoY); GAAP diluted EPS $2.70 (+1%); Non-GAAP diluted EPS $3.67 (+8%).
Biogen Q4 revenue $2.4B, GAAP EPS $1.71; 2024 Non-GAAP EPS guidance $15-$16
Q4 2023 revenue $2.4B (-6% YoY); GAAP EPS $1.71 vs $3.79; Non-GAAP EPS $2.95 vs $4.05
Requires disclosure of derivative/synthetic long positions from stockholders proposing business or nominations.
Biogen Q3 GAAP loss $0.47/sh, revenue $2.53B; updates FY guidance, highlights LEQEMBI
Revenue $2.53B (+1% YoY, +3% CC); GAAP diluted EPS $(0.47); Non-GAAP diluted EPS $4.36 (-9% YoY).
Biogen elects Monish Patolawala to board effective Jan 1, 2024
Monish Patolawala elected as director to fill a vacancy; term expires at 2024 Annual Meeting.
Biogen Board adopts annual Say-on-Pay vote after stockholder advisory vote
Stockholders voted in favor of annual Say-on-Pay frequency at June 26, 2023 annual meeting.
Biogen completes Reata acquisition; SKYCLARYS launch underway in U.S.
Acquired SKYCLARYS (omaveloxolone), first FDA-approved treatment for Friedreich's ataxia.
Biogen secures $1.5B term loan to fund Reata acquisition; bridge loan canceled
$1.5B unsecured term loan facility split into $750M 364-day Tranche A and $750M 3-year Tranche B.
Biogen to acquire Reata Pharmaceuticals for $172.50 per share in cash
Acquisition of Reata for $172.50 per share cash; Reata board unanimously approved.
Biogen to acquire Reata for $172.50/share, ~$7.3B enterprise value
Deal price $172.50/share in cash; total enterprise value ~$7.3 billion.
Biogen Q2 revenue $2.46B (-5% YoY); launches LEQEMBI, announces net $700M cost savings by 2025
Q2 revenue $2,456M; GAAP EPS $4.07, non-GAAP EPS $4.02; EPS down 44% and 23% YoY respectively.
Biogen shareholders elect directors, ratify auditor, approve say-on-pay at 2023 annual meeting
Seven incumbent directors re-elected; Susan K. Langer elected with 64M for, 46.6M against, 8.5M abstentions.
EU extends Tecfidera market exclusivity to Feb 2025
European Commission notified Biogen that Tecfidera's regulatory market protection extends to February 2, 2025.
Q1 revenue $2,463M (-3% YoY); GAAP EPS $2.67 (+30%); Non-GAAP EPS $3.40 (-6%).
Biogen amends bylaws to change 'Chairman' title to 'Chair'
Board approved Fourth Amended and Restated Bylaws effective April 12, 2023.
Biogen Chair Stelios Papadopoulos to step down; Caroline D. Dorsa elected as new Chair
Stelios Papadopoulos will not stand for re-election at the 2023 Annual Meeting; departure unrelated to any disagreement with Board or Company.
Biogen Q4 2022 rev $2.54B; GAAP EPS $3.79; guides FY2023 Non-GAAP EPS $15-$16
Q4 revenue $2,544M, GAAP EPS $3.79, Non-GAAP EPS $4.05.
Biogen appoints Christopher Viehbacher as President and CEO effective Nov 14, 2022
Viehbacher succeeds Michel Vounatsos, who steps down as CEO and from the Board.
Biogen Q3 2022 revenue $2,508M; GAAP EPS $7.84; raises full-year guidance
Q3 revenue $2,508M, down 10% YoY; MS revenue $1,621M (-11%), SPINRAZA $431M (-3%), Biosimilars $188M (-7%).
Biogen Q2 GAAP EPS $7.24, revenue $2.59B down 7% YoY; raises FY2022 guidance
Revenue $2,589M (-7% YoY); GAAP EPS $7.24, Non-GAAP EPS $5.25.
Biogen Q2 revenue $2.59B, GAAP EPS $7.24; raises full-year guidance
Q2 total revenue $2,589M, down 7% YoY; MS revenue $1,719M (-4%), SPINRAZA $431M (-14%).
Biogen EVP Chirfi Guindo to depart June 30; say-on-pay passes with 48% against
Chirfi Guindo, EVP Global Product Strategy, leaves June 30, 2022 for a role outside Biogen.
Biogen Q1 revenue down 6%, EPS miss; CEO Michel Vounatsos to step down; ADUHELM infrastructure cut
Q1 revenue $2.532B (-6% YoY); GAAP EPS $2.06, Non-GAAP EPS $3.62, both impacted by $0.76 ADUHELM write-offs
As previously announced, Ms. Kramer has been appointed the Company’s Chief Financial Officer, effective upon the retirement of Michael McDonnell, the Company’s current Chief Financial Officer.
On January 13, 2025, Biogen Inc. (the “Company”) appointed Sean Godbout as Vice President, Chief Accounting Officer & Global Corporate Controller and designated Mr. Godbout as the Company’s principal accounting officer, in each case effective as of March 1, 2025.
Mr. McDonnell will retire on March 1, 2025.
On October 28, 2024, Michael McDonnell, Chief Financial Officer of Biogen Inc. (the “Company”) notified the Company that he will retire from the Company effective February 28, 2025.
Robin Kramer, the Company’s Chief Accounting Officer and Head of Global Business Services and Treasury has been appointed Chief Financial Officer effective upon Mr. McDonnell’s retirement.
On September 11, 2024, the Board of Directors (the “Board”) of Biogen Inc. (the “Company”) increased the size of the Board and elected Lloyd B. Minor, M.D. and Sir Menelas (Mene) Pangalos, Ph.D. as directors, effective October 1, 2024 and January 1, 2025, respectively, with each director’s term expiring at the Company’s 2025 Annual Meeting of Stockholders.
On September 11, 2024, the Board of Directors (the “Board”) of Biogen Inc. (the “Company”) increased the size of the Board and elected Lloyd B. Minor, M.D. and Sir Menelas (Mene) Pangalos, Ph.D. as directors, effective October 1, 2024 and January 1, 2025, respectively, with each director’s term expiring at the Company’s 2025 Annual Meeting of Stockholders.
On November 6, 2023, the Board of Directors (the “Board”) of Biogen Inc. (the “Company”) elected Monish Patolawala as a director (term to expire at the 2024 Annual Meeting) to fill a vacancy, effective January 1, 2024.
Michel Vounatsos will step down as Biogen’s CEO and will resign from the Board.
appointed Christopher A. Viehbacher, age 62, to serve as President and CEO of Biogen, beginning November 14, 2022.
Mr. Viehbacher will succeed Michel Vounatsos as director of Biogen effective November 14, 2022
On June 21, 2022, Chirfi Guindo, Executive Vice President for Global Product Strategy and Commercialization announced that he has accepted a new role outside of Biogen, Inc. (the “Company”).
Max materiality 0.95 · Median 0.70 · Most common event earnings